Trial Profile
Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Ropidoxuridine (Primary)
- Indications Brain metastases
- Focus Adverse reactions
- 25 Jan 2024 Planned End Date changed from 24 Feb 2024 to 22 Sep 2024.
- 25 Feb 2023 Planned End Date changed from 31 Dec 2023 to 24 Feb 2024.
- 06 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.